IDEAYA Biosciences, Inc. - IDYA
About Gravity Analytica
Recent News
- 12.11.2025 - IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
- 12.10.2025 - IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
- 12.01.2025 - IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
- 11.28.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 11.24.2025 - IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
- 11.04.2025 - IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
- 10.31.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 10.27.2025 - IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
- 10.20.2025 - IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
- 10.20.2025 - IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress